Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sharon Choo is active.

Publication


Featured researches published by Sharon Choo.


Journal of Experimental Medicine | 2010

B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans.

Danielle T. Avery; Elissa K. Deenick; Cindy S. Ma; Santi Suryani; Nicholas Simpson; Gary Y. Chew; Tyani D. Chan; Umamainthan Palendira; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Sharon Choo; Karl E. Bleasel; Jane Peake; Cecile King; Martyn A. French; Dan Engelhard; Sami Al-Hajjar; Saleh Al-Muhsen; Klaus Magdorf; Joachim Roesler; Peter D. Arkwright; Pravin Hissaria; D. Sean Riminton; Melanie Wong; Robert Brink; David A. Fulcher; Jean-Laurent Casanova; Matthew C. Cook; Stuart G. Tangye

Engagement of cytokine receptors by specific ligands activate Janus kinase–signal transducer and activator of transcription (STAT) signaling pathways. The exact roles of STATs in human lymphocyte behavior remain incompletely defined. Interleukin (IL)-21 activates STAT1 and STAT3 and has emerged as a potent regulator of B cell differentiation. We have studied patients with inactivating mutations in STAT1 or STAT3 to dissect their contribution to B cell function in vivo and in response to IL-21 in vitro. STAT3 mutations dramatically reduced the number of functional, antigen (Ag)-specific memory B cells and abolished the ability of IL-21 to induce naive B cells to differentiate into plasma cells (PCs). This resulted from impaired activation of the molecular machinery required for PC generation. In contrast, STAT1 deficiency had no effect on memory B cell formation in vivo or IL-21–induced immunoglobulin secretion in vitro. Thus, STAT3 plays a critical role in generating effector B cells from naive precursors in humans. STAT3-activating cytokines such as IL-21 thus underpin Ag-specific humoral immune responses and provide a mechanism for the functional antibody deficit in STAT3-deficient patients.


Blood | 2012

Functional STAT3 deficiency compromises the generation of human T follicular helper cells

Cindy S. Ma; Danielle T. Avery; Anna Chan; Marcel Batten; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Peter D. Arkwright; Alexandra Y. Kreins; Diana Averbuch; Dan Engelhard; Klaus Magdorf; Sara Sebnem Kilic; Yoshiyuki Minegishi; Shigeaki Nonoyama; Martyn A. French; Sharon Choo; Joanne Smart; Jane Peake; Melanie Wong; Paul Gray; Matthew C. Cook; David A. Fulcher; Jean-Laurent Casanova; Elissa K. Deenick; Stuart G. Tangye

T follicular helper (Tfh) cells are critical for providing the necessary signals to induce differentiation of B cells into memory and Ab-secreting cells. Accordingly, it is important to identify the molecular requirements for Tfh cell development and function. We previously found that IL-12 mediates the differentiation of human CD4(+) T cells to the Tfh lineage, because IL-12 induces naive human CD4(+) T cells to acquire expression of IL-21, BCL6, ICOS, and CXCR5, which typify Tfh cells. We have now examined CD4(+) T cells from patients deficient in IL-12Rβ1, TYK2, STAT1, and STAT3 to further explore the pathways involved in human Tfh cell differentiation. Although STAT1 was dispensable, mutations in IL12RB1, TYK2, or STAT3 compromised IL-12-induced expression of IL-21 by human CD4(+) T cells. Defective expression of IL-21 by STAT3-deficient CD4(+) T cells resulted in diminished B-cell helper activity in vitro. Importantly, mutations in STAT3, but not IL12RB1 or TYK2, also reduced Tfh cell generation in vivo, evidenced by decreased circulating CD4(+)CXCR5(+) T cells. These results highlight the nonredundant role of STAT3 in human Tfh cell differentiation and suggest that defective Tfh cell development and/or function contributes to the humoral defects observed in STAT3-deficient patients.


Blood | 2011

X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease

Claire Booth; Kimberly Gilmour; Paul Veys; Andrew R. Gennery; Mary Slatter; Helen Chapel; Paul T. Heath; Colin G. Steward; Owen P. Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stéphane Blanche; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve De Saint-Basile; Michael H. Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan C. Lankester; Nico G. Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi

X-linked lymphoproliferative disease (XLP1) is a rare immunodeficiency characterized by severe immune dysregulation and caused by mutations in the SH2D1A/SAP gene. Clinical manifestations are varied and include hemophagocytic lymphohistiocytosis (HLH), lymphoma and dysgammaglobulinemia, often triggered by Epstein-Barr virus infection. Historical data published before improved treatment regimens shows very poor outcome. We describe a large cohort of 91 genetically defined XLP1 patients collected from centers worldwide and report characteristics and outcome data for 43 patients receiving hematopoietic stem cell transplant (HSCT) and 48 untransplanted patients. The advent of better treatment strategies for HLH and malignancy has greatly reduced mortality for these patients, but HLH still remains the most severe feature of XLP1. Survival after allogeneic HSCT is 81.4% with good immune reconstitution in the large majority of patients and little evidence of posttransplant lymphoproliferative disease. However, survival falls to 50% in patients with HLH as a feature of disease. Untransplanted patients have an overall survival of 62.5% with the majority on immunoglobulin replacement therapy, but the outcome for those untransplanted after HLH is extremely poor (18.8%). HSCT should be undertaken in all patients with HLH, because outcome without transplant is extremely poor. The outcome of HSCT for other manifestations of XLP1 is very good, and if HSCT is not undertaken immediately, patients must be monitored closely for evidence of disease progression.


The Journal of Allergy and Clinical Immunology | 2012

Increasing the accuracy of peanut allergy diagnosis by using Ara h 2

Thanh Dang; Mimi L.K. Tang; Sharon Choo; Paul V. Licciardi; Jennifer J. Koplin; Pamela E. Martin; Tina Tan; Lyle C. Gurrin; Anne-Louise Ponsonby; Dean Tey; Marnie Robinson; Shyamali C. Dharmage; Katrina J. Allen

BACKGROUND Measurement of whole peanut-specific IgE (sIgE) is often used to confirm sensitization but does not reliably predict allergy. Ara h 2 is the dominant peanut allergen detected in 90% to 100% of patients with peanut allergy and could help improve diagnosis. OBJECTIVES We sought to determine whether Ara h 2 testing might improve the accuracy of diagnosing peanut allergy and therefore circumvent the need for an oral food challenge (OFC). METHODS Infants from the population-based HealthNuts study underwent skin prick tests to determine peanut sensitization and subsequently underwent a peanut OFC to confirm allergy status. In a stratified random sample of 200 infants (100 with peanut allergy and 100 with peanut tolerance), whole peanut sIgE and Ara h 2 sIgE levels were quantified by using fluorescence enzyme immunoassay. RESULTS By using the previously published 95% positive predictive value of 15 kU(A)/L for whole peanut sIgE, a corresponding specificity of 98% (95% CI, 93% to 100%) was found in this study cohort. At the equivalent specificity of 98%, the sensitivity of Ara h 2 sIgE is 60% (95% CI, 50% to 70%), correctly identifying 60% of subjects with true peanut allergy compared with only 26% correctly identified by using whole peanut sIgE. We report that when using a combined approach of plasma sIgE testing for whole peanut followed by Ara h 2 for the diagnosis of peanut allergy, the number of OFCs required is reduced by almost two thirds. CONCLUSION Ara h 2 plasma sIgE test levels provide higher diagnostic accuracy than whole peanut plasma sIgE levels and could be considered a new diagnostic tool to distinguish peanut allergy from peanut tolerance, which might reduce the need for an OFC.


Haematologica | 2013

Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27

Elisabeth Salzer; Svenja Daschkey; Sharon Choo; Michael Gombert; Elisangela Santos-Valente; Sebastian Ginzel; Martina Schwendinger; Oskar A. Haas; Gerhard Fritsch; Winfried F. Pickl; Elisabeth Förster-Waldl; Arndt Borkhardt; Kaan Boztug; Kirsten Bienemann; Markus G. Seidel

CD27, a tumor necrosis factor receptor family member, interacts with CD70 and influences T-, B- and NK-cell functions. Disturbance of this axis impairs immunity and memory generation against viruses including Epstein Barr virus (EBV), influenza, and others. CD27 is commonly used as marker of memory B cells for the classification of B-cell deficiencies including common variable immune deficiency. Flow cytometric immunophenotyping including expression analysis of CD27 on lymphoid cells was followed by capillary sequencing of CD27 in index patients, their parents, and non-affected siblings. More comprehensive genetic analysis employed single nucleotide polymorphism-based homozygosity mapping and whole exome sequencing. Analysis of exome sequencing data was performed at two centers using slightly different data analysis pipelines, each based on the Genome Analysis ToolKit Best Practice version 3 recommendations. A comprehensive clinical characterization was correlated to genotype. We report the simultaneous confirmation of human CD27 deficiency in 3 independent families (8 patients) due to a homozygous mutation (p. Cys53Tyr) revealed by whole exome sequencing, leading to disruption of an evolutionarily conserved cystein knot motif of the transmembrane receptor. Phenotypes varied from asymptomatic memory B-cell deficiency (n=3) to EBV-associated hemophagocytosis and lymphoproliferative disorder (LPD; n=3) and malignant lymphoma (n=2; +1 after LPD). Following EBV infection, hypogammaglobulinemia developed in at least 3 of the affected individuals, while specific anti-viral and anti-polysaccharide antibodies and EBV-specific T-cell responses were detectable. In severely affected patients, numbers of iNKT cells and NK-cell function were reduced. Two of 8 patients died, 2 others underwent allogeneic hematopoietic stem cell transplantation successfully, and one received anti-CD20 (rituximab) therapy repeatedly. Since homozygosity mapping and exome sequencing did not reveal additional modifying factors, our findings suggest that lack of functional CD27 predisposes towards a combined immunodeficiency associated with potentially fatal EBV-driven hemo-phagocytosis, lymphoproliferation, and lymphoma development.


Journal of Experimental Medicine | 2013

Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells

Elissa K. Deenick; Danielle T. Avery; Anna Chan; Lucinda J. Berglund; Megan L. Ives; Leen Moens; Jennifer Stoddard; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Miyuki Tsumura; Masao Kobayashi; Peter D. Arkwright; Diana Averbuch; Dan Engelhard; Joachim Roesler; Jane Peake; Melanie Wong; Stephen Adelstein; Sharon Choo; Joanne Smart; Martyn A. French; David A. Fulcher; Matthew C. Cook; Capucine Picard; Anne Durandy; Christoph Klein; Steven M. Holland; Gulbu Uzel; Jean-Laurent Casanova; Cindy S. Ma

Memory B cells, unlike naive B cells, require a reduced level of STAT3 activation to differentiate into antibody-secreting plasmablasts in response to IL-10 and IL-21; however, this process requires IL-21R expression in both naive and memory cells.


PLOS Biology | 2011

Molecular Pathogenesis of EBV Susceptibility in XLP as Revealed by Analysis of Female Carriers with Heterozygous Expression of SAP

Umaimainthan Palendira; Carol Low; Anna Chan; Andrew D. Hislop; Edwin Ho; Tri Giang Phan; Elissa K. Deenick; Matthew C. Cook; D. Sean Riminton; Sharon Choo; Richard Loh; Frank Alvaro; Claire Booth; H. Bobby Gaspar; Alessandro Moretta; Rajiv Khanna; Alan B. Rickinson; Stuart G. Tangye

Analysis of females carriers of the X-linked lymphoproliferative (XLP) trait reveals the mechanism underlying exquisite sensitivity of XLP patients to often-fatal infection with the normally innocuous Epstein-Barr virus.


BMJ | 2008

Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study

Liew Woei Kang; Nigel W. Crawford; Mimi L.K. Tang; Jim Buttery; Jenny Royle; Michael Gold; Christine Ziegler; Patrick Quinn; Sonja Elia; Sharon Choo

Objective To describe the outcomes of clinical evaluation, skin testing, and vaccine challenge in adolescent schoolgirls with suspected hypersensitivity to the quadrivalent human papillomavirus vaccine introduced in Australian schools in 2007. Design Retrospective cohort study. Setting Two tertiary paediatric allergy centres in Victoria and South Australia, Australia. Participants 35 schoolgirls aged 12 to 18.9 years with suspected hypersensitivity reactions to the quadrivalent human papillomavirus vaccine. Main outcome measures Clinical review and skin prick and intradermal testing with the quadrivalent vaccine and subsequent challenge with the vaccine. Results 35 schoolgirls with suspected hypersensitivity to the quadrivalent human papillomavirus vaccine were notified to the specialised immunisation services in 2007, after more than 380 000 doses had been administered in schools. Of these 35 schoolgirls, 25 agreed to further evaluation. Twenty three (92%) experienced reactions after the first dose. Thirteen (52%) experienced urticaria or angio-oedema, and of these, two experienced anaphylaxis. Thirteen had generalised rash, one with angio-oedema. The median time to reaction was 90 minutes. Nineteen (76%) underwent skin testing with the quadrivalent vaccine: all were skin prick test negative and one was intradermal test positive. Eighteen (72%) were subsequently challenged with the quadrivalent vaccine and three (12%) elected to receive the bivalent vaccine. Seventeen tolerated the challenge and one reported limited urticaria four hours after the vaccine had been administered. Only three of the 25 schoolgirls were found to have probable hypersensitivity to the quadrivalent vaccine. Conclusion True hypersensitivity to the quadrivalent human papillomavirus vaccine in Australian schoolgirls was uncommon and most tolerated subsequent doses.


Journal of Experimental Medicine | 2012

Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus

Umaimainthan Palendira; Carol Low; Andrew I. Bell; Cindy S. Ma; Rachel J. M. Abbott; Tri Giang Phan; D. Sean Riminton; Sharon Choo; Joanne Smart; Vassilios Lougaris; Silvia Giliani; Rebecca H. Buckley; Bodo Grimbacher; Frank Alvaro; Amy D. Klion; Kim E. Nichols; Stephen Adelstein; Alan B. Rickinson; Stuart G. Tangye

In patients with XLP, a primary immunodeficiency caused by mutations in SH2D1A, EBV infection can lead to somatic reversion of the disease-causing mutation selectively in effector memory CD8 T cells; reverted CD8 cells are better able to respond to and kill EBV-infected cells.


The Journal of Allergy and Clinical Immunology | 2013

Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function.

Megan L. Ives; Cindy S. Ma; Umaimainthan Palendira; Anna Chan; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Peter D. Arkwright; Dan Engelhard; Diana Averbuch; Klaus Magdorf; Joachim Roesler; Jane Peake; Melanie Wong; Stephen Adelstein; Sharon Choo; Joanne Smart; Martyn A. French; David A. Fulcher; Matthew C. Cook; Capucine Picard; Anne Durandy; Miyuki Tsumura; Masao Kobayashi; Gulbu Uzel; Jean-Laurent Casanova; Stuart G. Tangye; Elissa K. Deenick

BACKGROUND The capacity of CD8(+) T cells to control infections and mediate antitumor immunity requires the development and survival of effector and memory cells. IL-21 has emerged as a potent inducer of CD8(+) T-cell effector function and memory development in mouse models of infectious disease. However, the role of IL-21 and associated signaling pathways in protective CD8(+) T-cell immunity in human subjects is unknown. OBJECTIVE We sought to determine which signaling pathways mediate the effects of IL-21 on human CD8(+) T cells and whether defects in these pathways contribute to disease pathogenesis in patients with primary immunodeficiencies caused by mutations in components of the IL-21 signaling cascade. METHODS Human primary immunodeficiencies resulting from monogenic mutations provide a unique opportunity to assess the requirement for particular molecules in regulating human lymphocyte function. Lymphocytes from patients with loss-of-function mutations in signal transducer and activator of transcription 1 (STAT1), STAT3, or IL-21 receptor (IL21R) were used to assess the respective roles of these genes in human CD8(+) T-cell differentiation in vivo and in vitro. RESULTS Mutations in STAT3 and IL21R, but not STAT1, led to a decrease in multiple memory CD8(+) T-cell subsets in vivo, indicating that STAT3 signaling, possibly downstream of IL-21R, regulates the memory cell pool. Furthermore, STAT3 was important for inducing the lytic machinery in IL-21-stimulated naive CD8(+) T cells. However, this defect was overcome by T-cell receptor engagement. CONCLUSION The IL-21R/STAT3 pathway is required for many aspects of human CD8(+) T-cell behavior but in some cases can be compensated by other signals. This helps explain the relatively mild susceptibility to viral disease observed in STAT3- and IL-21R-deficient subjects.

Collaboration


Dive into the Sharon Choo's collaboration.

Top Co-Authors

Avatar

Joanne Smart

Royal Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Stuart G. Tangye

Garvan Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Theresa Cole

Royal Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Cindy S. Ma

Garvan Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Elissa K. Deenick

Garvan Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Melanie Wong

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Matthew C. Cook

Australian National University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge